Our Company

About 60 Degrees Pharmaceuticals

Our company history and mission

60 Degrees Pharmaceuticals was founded in 2010 with a mission to realize new ways to improve and extend people’s lives by discovering, developing, and distributing new best-in-class medicines for the treatment and prevention of tropical diseases. The Company is now developing and commercializing products more broadly for infectious disease.


We apply the same passion, energy, and culture of innovation that allowed the successful approval of ARAKODA® (tafenoquine) to making a difference in the world. We are committed to finding the tools and strategies that will help us overcome some of the planet’s greatest health challenges.

Return for investors

Our core business is delivering infectious disease drug development and commercialization while providing an attractive ROI.

Our collaborative approach

60 Degrees Pharmaceuticals has embraced an open innovation approach to reduce the time, cost, and risk needed to build a portfolio of drug discovery and development projects. We collaborate with leading research institutions to discover and develop medicines for infectious diseases.

Our vision

Our intention is to become the trusted leader in changing the practice of malaria prevention and forging new weapons to combat life-threatening infectious diseases.


Headquarters: Washington, DC (USA)

Research & Development: Australia

Executive Committee

Geoffrey Dow, Chief Executive, President and Director

Geoffrey Dow is the CEO, President, and sole Director of 60 Degrees Pharmaceuticals, Inc. He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60 Degrees Pharmaceuticals in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for ARAKODA® (tafenoquine) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. He also published several important safety reviews, clinical trials, and non-clinical studies. Dr. Dow’s ultimate goal is to develop and secure regulatory approval and commercial success of products for new indications in infectious disease. He holds a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (1994), a Ph.D. in Veterinary and Biomedical Science from Murdoch University (2000), and an MBA from the University of Maryland at College Park (2012).

Tyrone Miller, Treasurer

Tyrone Miller is the Treasurer of 60 Degrees Pharmaceuticals, Inc. He joined the company in 2014 and has held various roles including Chief Financial Officer. He raised over $6 million in external financing and established a multinational financial reporting system. He provides strategic advice in areas of financing and business planning to the company. He is also the founder and Principal of Tax & Accounting Practice at Miller Tax & Advisory since 2011, where he advises business owners on accounting, financial, and tax matters and has designed accounting systems for private businesses. Prior to that, he was a Senior Accountant at Sachs Figurelli, LLC from 2002 to 2011 where he prepared and processed corporate and individual tax returns, consulted on accounting processes for various businesses, and managed staff in preparation and processing of payroll and personal property returns. He is a Certified Public Accountant and received a Bachelor’s of Business Administration with a concentration in International Business from Emory University in 1996.

Bryan Smith, Chief Medical Officer

Bryan Smith is the Chief Medical Officer of 60 Degrees Pharmaceuticals, Inc. He is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. He has over 30 years of experience in governmental research and leadership and is a retired military colonel. He joined the company in 2016 and works with the senior management team to establish all functional areas, including compliance with laws and regulations and overseeing research and development projects. Dr. Smith is also a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC since 2019, where he is responsible for developing clinical development plans, managing clinical and regulatory projects, and designing and writing clinical trial protocols. He has also served as the Chief Medical Officer and member of Amivas LLC, where he established all functional areas required to secure FDA approvals. Additionally, from 2016 to 2019, he was the Principal Medical Consultant at Clinical Network Services, Inc. where he provided medical, clinical pharmacology, regulatory, and translational medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small molecules, and large molecules in a range of therapeutic areas. He holds a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.

Kristen Landon, Chief Commercial Officer

Kristen Landon is the Chief Commercial Officer. Ms. Landon joined us in 2024 and brings over 26 years’ experience building and transforming pharmaceutical brands in both start-up and large multinational companies. Ms. Landon has launched and relaunched over a dozen brands, many with peak revenues in excess of $100 million across therapeutic categories including women’s health, infectious disease, dermatology, nephrology, and hematology/oncology. Most recently, Ms. Landon served as Senior Vice President of Marketing and Communications at TherapeuticsMD with responsibility for the branded portfolio, marketing insights, and corporate communications. Prior commercial leadership roles include VP Marketing at Radius Health, VP Marketing at Sprout Pharmaceuticals (acquired by Valeant), Executive Director Women’s Health at Actavis Plc, and positions of increasing responsibility in sales and marketing at Forest Labs, Abbott Labs, and Novartis. Ms. Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

Jennifer Herz, Director

As 60 Degrees Pharmaceuticals’ head consultant, Jennifer brings over 20 years of commercial, business development, and scientific affairs experience in the bio-pharma industry. Her background is very vaccine focused. As the first Managing Director of Sanofi Pasteur in Australia, she developed the company into a major provider of vaccines in Australia, commercially launching five new vaccines. She was also the founding Chair of the Medicines Australia Vaccine Industry Group and served on the Board of Medicines Australia.


Her concurrent position is as co-founder and director at Biointelect Pty. Ltd., a life science consulting organization. Jennifer previously held the position of Senior Director at Astra Zeneca Europe.


Since 2007, Jennifer has worked as a consultant in both Europe and Australia to both biotech companies and multinational pharmaceutical companies, assisting with strategic planning, market access, public affairs, medical, regulatory and scientific affairs, and training.


Cheryl Xu

Cheryl Xu is a director nominee who previously served as Biogen’s VP of Public Policy & Government Affairs. Previously, she ran a consulting business advising multinational companies on market access and expansion in China. She has also provided consultations to the US and Chinese governments on pharmaceutical policies, and was the Director of International Finance at Pharmacia. She holds a B.S. in Physics from Peking University and an MBA in Finance from Washington University.

Stephen Toovey

Dr. Stephen Toovey is a director nominee who is an infectious and tropical disease physician. He has experience in the pharmaceutical industry and academia in both developed and developing countries. He currently specializes in the research of influenza and other respiratory viruses, malaria, rabies and the neurological aspects of infectious diseases. He is CEO of Pegasus, a medical and scientific services company, and advises pharmaceutical companies and biotech organizations on infectious-disease-related matters. He has founded several pharmaceutical and pharma-related companies, including co-founding Ark Biosciences in 2014 where he served as CMO until 2020. He taught at Royal Free and teaches at University College Medical School and is deputy editor of the journal Travel Medicine and Infectious Disease. He has authored over 100 publications and presented at over 50 scientific meetings, and holds a PhD from the University of Ghent.

Paul Field

Paul Field is a director nominee with over 30 years of business development experience in the biopharmaceutical industry across a range of therapeutic areas. He is currently a corporate advisor at several companies, including Imunexus Ltd. and the Global Antibiotic R&D Partnership (Geneva). Previously, he was the life sciences specialist at the Australian government agency Austrade, where he facilitated foreign investment in Australian research on neglected tropical diseases, autoimmune diseases, cancer, and other programs. He has served on multiple boards of directors and is a Fellow of the Australian Institute of Company Directors.

Charles Allen

Charles Allen is a nominee for the board of 60 Degrees Pharmaceuticals, Inc. and has served as CEO of BTCS Inc. since February 2014 and as Chairman of BTCS since September 2014. He is responsible for BTCS’ overall corporate strategy and direction. He also serves as a director of Innovation1 Biotech Inc. since December 2022. He has extensive experience in business strategy, investment banking and capital markets transactions, such as financings, initial public offerings, and mergers and acquisitions. He has served as a managing director at various boutique investment banks and has worked domestically and internationally on projects in technology, media, natural resources, logistics, medical services, and financial services. He holds a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business Administration from the Mason School of Business at the College of William & Mary.

FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, ARAKODA, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: uncertainty around and costs associated with the development of ARAKODA and our other product candidates; dependence on management, directors and other key personnel; our need for substantial additional funding; our dependence on the success of our most advanced product candidates; risks related to the regulatory approval process; risks associated with the clinical development process and reliance on interim or topline clinical trial results; risks related to healthcare laws and other legal compliance matters; risks related to potential commercialization; risks related to manufacturing and our dependence on third parties; risks relating to intellectual property; our ability to maintain effective internal control over financial reporting and the significant costs as a result of operating as a company. These important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Annual deaths from malaria globally


Travelers to malaria endemic regions per annum


Annual dengue infections globally


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036